Medical research
Stoke Therapeutics Presents Two-Year Data from FALCON Study on Autosomal Dominant Optic Atrophy (ADOA)
Stoke Therapeutics, a biotechnology company dedicated to restoring protein expression through RNA medicines, presented two-year data from the FALCON study at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting. The FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA) (n=47), aimed to